Upcoming Events

  • Event Details

    • The 2025 Extraordinary General Meeting will take place on Friday, Aug 1, 2025 at 9AM KST at the Daejeon Convention Center, 3FL conference Hall, 107 Expo-ro, Yuseong-gu, Daejeon, South Korea

    • To accommodate shareholders who are unable to attend The 2025 Extraordinary General Meeting in person, we offer a live online broadcast.

      • The online broadcast is limited to shareholders who complete pre-registration.

      • In accordance with Article 355 of the Korean Commercial Act, we are required to verify shareholder status based on the record date of the shareholder registry.

      • Please register within the designated period by following the details below (Simultaneous interpretation will be provided.)

    • Broadcast date and time : Friday, August 1, 2025, 09:00 (AM KST)

    Pre-registration Information

    • Pre-registration period : Thursday, July 17, 2025, 18:00 (PM KST) to Friday, August 1, 2025, 08:50 (AM KST)

    • Pre-registration link : Click

    • To confirm your eligibility as a shareholder, please see below to submit documentation.

      • For Individual Shareholders : A copy of your resident registration card or driver’s license (Foreign Individual Shareholder: Copy of Foreigner Registration Card)

      • For Institutional Shareholders, A copy of your business registration certificate

    • Please be advised that online voting during the live broadcast is not recognized under current laws. Shareholders who will attend the AGM via broadcast are kindly requested to submit their votes in advance of the meeting date.

Past Events

Sophia (Sujin) Kim Sophia (Sujin) Kim

2025 9th Annual General Meeting

Event Details

The 2025 9th Annual General Meeting took place on Friday, March 28, 2025 at 9AM KST at the Daejeon Convention Center, 3FL conference Hall, 107 Expo-ro, Yuseong-gu, Daejeon, South Korea

Presentation

Proposal Reference Material ( KR / EN )

Annual Report

Outcomes : KR / EN

A total of 12,106,876 shares were represented in person or by proxy at the Company's 9th Annual Meeting of Shareholders: the representation rate was 65.69% based on the total shares outstanding and entitled to vote held by persons other than the Principal Shareholder and its Affiliates

Proposal No. 1 : Approval of the FY2024 Financial Statements | Approved
Proposal No. 2 : Approval of Director Remuneration Limit | Approved
Proposal No. 3 : Approval of Auditor Renumeration Limit | Approved
Proposal No. 4 : Approval of Amendments to the Articles of Incorporation | Approved

Read More
Kayla (Gyebang) Mo Kayla (Gyebang) Mo

Orum Therapeutics Announces Three Presentations At AACR 2023

Poster Title:

  • PD-1-Cbl-bi TPS² preclinical poster

    A novel antibody-enabled Dual-precision Targeted Protein Stabilization (TPS²) that augments anti-tumor immune response by targeting Cbl-b inhibitor to exhausted T cells while blocking checkpoint molecule, PD-1

  • ORM-6151 preclinical poster

    ORM-6151: A first-in-class CD33-antibody enabled GSPT1 degrader for AML

  • ORM-5029 predictive biomarker poster

    Development of RNAscope multiplex-based assay for exploratory pharmacodynamic biomarkers assessment in breast cancer patients from Phase I clinical trial of ORM-5029, a potent GSPT1 degrader

Date and Time: 4/17/2023, 9:00 AM - 12:30 PM ET

Read More